Table 2 Newly diagnosed cardiovascular disease after ICI initiation
Immune Checkpoint Inhibitor | Cardiomyopathy, n (%) | Heart failure, n (%) | Arrhythmia, n (%) | Pericardial disease, n (%) | Heart block, n (%) | Myocarditis, n (%) | Any cardiotoxicity, n (%) | Median (IQR) time to cardiotoxicity, days |
|---|---|---|---|---|---|---|---|---|
PD-1 inhibitors | ||||||||
nivolumab (n = 217) | 1 (0.46) | 10 (4.61) | 15 (6.91) | 7 (3.23) | 6 (2.76) | 1 (0.46) | 33 (15.21) | 52 (37–203) |
pembrolizumab (n = 123) | 0 | 6 (4.88) | 3 (2.44) | 1 (0.81) | 1 (0.81) | 0 | 11 (8.94) | 65 (30–175) |
PD-L1 inhibitors | ||||||||
atezolizumab (n = 17) | 0 | 1 (5.88) | 2 (11.76) | 0 | 0 | 0 | 3 (17.65) | 22 (2–172) |
durvalumab (n = 4) | 1 (25) | 0 | 0 | 0 | 0 | 0 | 1 (25.00) | 30 |
CTLA-4 inhibitor | ||||||||
ipilimumab (n = 13) | 0 | 4 (30.77) | 1 (7.69) | 0 | 1 (7.69) | 0 | 6 (46.15) | 709 (78–1469) |
CTLA-4 + PD-1/PD-L1 inhibitor combination | ||||||||
ipilimumab + nivolumab (n = 29) | 2 (6.9) | 1 (3.45) | 4 (13.79) | 0 | 1 (3.45) | 0 | 7 (24.14) | 95 (11–119) |
ipilimumab + pembrolizumab (n = 7) | 0 | 1 (14.29) | 1 (14.29) | 0 | 0 | 0 | 1 (14.29) | 62 |
tremelimumab + durvalumab (n = 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
PD-1/PD-L1 dual sequential | ||||||||
nivolumab - > pembrolizumab (n = 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
nivolumab - > atezolizumab (n = 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
pembrolizumab - > atezolizumab (n = 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Three-drug sequential | ||||||||
ipilimumab + nivolumab - > pembrolizumab (n = 1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Total (n = 424) | 4 (0.94) | 23 (5.42) | 26 (6.13) | 8 (1.89) | 9 (2.12) | 1 (0.24) | 62 (14.62) | 63 (30–175) |